新型敏感免疫检测靶向MTX-LAM表位达到WHO结核诊断性能目标
研究评估了100种新型单克隆抗体对在电化学发光平台上检测尿液中脂阿拉伯甘露聚糖(LAM)的潜力。在75例疑似结核成人尿样的回顾性病例对照研究中,最佳抗体对达到飞摩尔级分析灵敏度,总体临床灵敏度93%(CI 80%-97%)、特异性97%(CI 85%-100%);HIV阴性涂片阳性者灵敏度80%(CI 55%-93%),而Alere LF-LAM在相同样本集中总体灵敏度33%(CI 20%-48%)、HIV阴性者13%(CI 4%-38%)。
要点
- 最佳抗体对检测尿LAM的临床灵敏度93%、特异性97%,优于Alere LF-LAM的33%。
- 在HIV阴性涂片阳性结核患者中,新检测灵敏度达80%,而Alere LF-LAM仅13%。
- 捕获抗体靶向MTX依赖性LAM表位,对结核分枝杆菌复合群特异,不与快生长分枝杆菌交叉。
核心结论
- 改进的检测方法和试剂可提高尿LAM诊断结核的准确性,新型LAM即时检测有望达到WHO结核诊断性能目标。
研究设计与样本
- 在电化学发光平台上筛选100种靶向不同LAM表位的单克隆抗体对,并将筛选出的12种最佳抗体对用于回顾性病例对照研究,样本为75例疑似结核成人的尿液。
主要发现
- 许多抗体对对纯化LAM反应性高,但检测临床尿样LAM效果差,提示不同来源LAM的抗原结构和免疫反应性存在差异。
- 最佳抗体对对LAM检测达到飞摩尔级分析灵敏度,总体临床灵敏度93%(CI 80%-97%)、特异性97%(CI 85%-100%)。
- 在HIV阴性且痰涂片阳性的结核患者中,新检测灵敏度为80%(CI 55%-93%)。
- 在相同样本集中,Alere LF-LAM总体灵敏度为33%(CI 20%-48%),HIV阴性者灵敏度为13%(CI 4%-38%)。
- 捕获抗体靶向LAM中独特的5-甲基硫代-d-木呋喃糖(MTX)依赖性表位,该表位对结核分枝杆菌复合群特异,与快生长分枝杆菌或其他细菌无交叉反应。
关键数值与推荐
- 最佳抗体对:分析灵敏度达飞摩尔级;总体临床灵敏度93%(CI 80%-97%),特异性97%(CI 85%-100%)。
- HIV阴性涂片阳性结核患者:新检测灵敏度80%(CI 55%-93%)。
- 相同样本集中Alere LF-LAM:总体灵敏度33%(CI 20%-48%),HIV阴性者灵敏度13%(CI 4%-38%)。
临床怎么用
- 该新型LAM检测方法在疑似结核成人中显示出高灵敏度和特异性,尤其在HIV阴性涂片阳性患者中优于现有Alere LF-LAM。
- 捕获抗体靶向MTX依赖性LAM表位,对结核分枝杆菌复合群特异,有助于提高尿LAM检测的诊断准确性。
局限性
- 研究为回顾性病例对照研究,样本量较小(75例疑似结核成人),需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The only currently commercialized point-of-care assay for tuberculosis (TB) that measures lipoarabinomannan (LAM) in urine (Alere LF-LAM) has insufficient sensitivity. We evaluated the potential of 100 novel monoclonal antibody pairs targeting a variety of LAM epitopes on a sensitive electrochemiluminescence platform to improve the diagnostic accuracy. In the screening, many antibody pairs showed high reactivity to purified LAM but performed poorly at detecting urinary LAM in clinical samples, suggesting differences in antigen structure and immunoreactivity of the different LAM sources. The 12 best antibody pairs from the screening were tested in a retrospective case-control study with urine samples from 75 adults with presumptive TB. The best antibody pair reached femtomolar analytical sensitivity for LAM detection and an overall clinical sensitivity of 93% (confidence interval [CI], 80% to 97%) and specificity of 97% (CI, 85% to 100%). Importantly, in HIV-negative subjects positive for TB by sputum smear microscopy, the test achieved a sensitivity of 80% (CI, 55% to 93%). This compares to an overall sensitivity of 33% (CI, 20% to 48%) of the Alere LF-LAM and a sensitivity of 13% (CI, 4% to 38%) in HIV-negative subjects in the same sample set. The capture antibody targets a unique 5-methylthio-d-xylofuranose (MTX)-dependent epitope in LAM that is specific to the Mycobacterium tuberculosis complex and shows no cross-reactivity with fast-growing mycobacteria or other bacteria. The present study provides evidence that improved assay methods and reagents lead to increased diagnostic accuracy. The results of this work have informed the development of a sensitive and specific novel LAM point-of-care assay with the aim to meet the WHO's performance target for TB diagnosis.
引用
- Sigal GB, Pinter A, Lowary TL, et al. A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis. J Clin Microbiol. 2018. PMID: 30257899. doi:10.1128/JCM.01338-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。